Cardiovascular risk during androgen deprivation therapy for prostate cancer: Should be monitored, and primary and secondary prevention optimised

BMJ (Online)

Volumn 343, Issue 7821, 2011, Pages

  Jones, Thomas Hugh ^a  

^a BARNSLEY HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GONADORELIN AGONIST; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIANDROGEN; TESTOSTERONE;

ANDROGEN DEFICIENCY; ANDROGEN DEPRIVATION THERAPY; BODY FAT DISTRIBUTION; CARDIOVASCULAR DISEASE; DISEASE ASSOCIATION; DYSLIPIDEMIA; EDITORIAL; EVIDENCE BASED MEDICINE; FOLLOW UP; GOOD CLINICAL PRACTICE; HUMAN; HYPERTENSION; INCIDENCE; INFLAMMATION; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; OBESITY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; SECONDARY PREVENTION; AGED; CHEMICALLY INDUCED DISORDER; MALE; PROSTATE TUMOR; RISK FACTOR;

AGED; ANDROGEN ANTAGONISTS; CARDIOVASCULAR DISEASES; HUMANS; MALE; PROSTATIC NEOPLASMS; RISK FACTORS; TESTOSTERONE;

EID: 84859004310     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.d3105     Document Type: Editorial

References (12)

1. Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society and American Urological Association: Endorsed by the American Society for Radiation Oncology. Circulation 2010;121:833-40.
2. Keating NL, O'Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol 2006;24:4448-56.
3. D'Amico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol 2007;25:2420-5.
4. Tsai HK, D'Amico AV, Sadetsky N, Chen MH, Carroll PR. Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality. J Natl Cancer Inst 2007;99:1516-24.
5. Saigal CS, Gore JL, Krupski TL, Hanley J, Schonlau M, Litwin MS; and the Urologic Diseases in America Project. Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer. Cancer 2007;110:1493-500.
6. Van Hemelrijk M, Garmo H, Holmberg L, Ingelsson E, Bratt O, Bill-Axelson A, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer; results from the Population-based PCBaSe Sweden. J Clin Oncol 2010;28:3448-56.
7. Bolla M, Van Tienhoven G, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol 2010;11:1066-73.
8. Jones TH. Testosterone deficiency: a cardiovascular risk factor? Trends Endocrinol Metab 2010;21:496-503.
9. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart 2010;96:1821-5.
10. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, et al. Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 2002;87:599-603.
11. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockade for prostate cancer. J Clin Endocrinol Metab 2006;91:1305-8.
12. Haider A, Yassin A, Saad F, Shabsigh R. Effect of androgen deprivation on glycaemic control and on cardiovascular risk factors in men with advanced prostate cancer with diabetes. Aging Male 2007;10:189-96.